Here's What You May Have Missed About Sarepta Therapeutics (SRPT)

By Tamara Parker • Monday, January 16 15:00 • Permanent Link

Shares of Biotechnology company Sarepta Therapeutics jumped 4.2% today. With many investors piling into SRPT without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

Sarepta Therapeutics has moved 91.6% over the last year, and the S&P 500 logged a change of -12.6%
SRPT has an average analyst rating of buy and is -16.09% away from its mean target price of $151 per share
Its trailing earnings per share (EPS) is $-4.29
Sarepta Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -29.6 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-4.91 and its forward P/E ratio is -25.8
The company has a Price to Book (P/B) ratio of 25.8 in contrast to the S&P 500's average ratio of 2.95
Sarepta Therapeutics is part of the Healthcare sector, which has an average P/E ratio of 13.21 and an average P/B of 4.07
The company has a free cash flow of $110,413,376.00, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.